Siena Biotech employs both novel target identification techniques (differential proteomics and bioinformatics) and knowledge based target selection (disease application and cheminformatics) to provide a balanced portfolio of risk and opportunity.

Target selection thus ranges from the use of proteomics based tools as highlighted in the European Union Framework VI supported project ADIT, a major project for the identification of novel Alzheimer’s Disease targets, to the use of phenotype screening to allow compound based or forward chemical genetics approaches.

Our focus on CNS targets enables a number of potentially interesting synergies between disease areas and the opportunity to explore more fully the role played by the targets of interest.
It is important for us to select targets where the mechanism of action of potential drug molecules can be investigated and utilized in their optimization.